Reuters logo
Axovant's Alzheimer's drug fails late-stage trial
September 26, 2017 / 11:13 AM / 3 months ago

Axovant's Alzheimer's drug fails late-stage trial

Sept 26 (Reuters) - Axovant Sciences Ltd said on Tuesday its experimental drug targeting Alzheimer’s patients failed to meet the main goals in a late-stage trial.

The drug, intepirdine, was being tested in patients with mild to moderate Alzheimer’s who did not respond to initial therapy, and was compared with a placebo.

Shares of the company were halted in premarket trading on Tuesday. (Reporting by Divya Grover; Editing by Sriraj Kalluvila)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below